USD 1.135
↓ -0.075 (-6.2%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | -6.2 | 20.7 | -7.7 | 65.7 | -33.6 | -77.3 | -69.2 | -89.1 | -88.3 | -88.3 |
| S&P 500 | -1.5 | -2.0 | 0.7 | 5.7 | 10.3 | 30.1 | 25.1 | 87.7 | 186.9 | 33067.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RVPH |
| name | Reviva Pharmaceuticals Holdings, Inc. |
| price | 1.135 |
| changes percentage | -6.1984 |
| change | -0.075 |
| day low | 1.0909 |
| day high | 1.2399 |
| year high | 5.67 |
| year low | 0.6 |
| market cap | 37955762 |
| price avg 50 | 1.2194 |
| price avg 200 | 2.02055 |
| exchange | NASDAQ |
| volume | 715436 |
| avg volume | 577437 |
| open | 1.2 |
| previous close | 1.21 |
| eps | -1.32 |
| pe | -0.86 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 33441200 |
| timestamp | 2024-11-15 18:42:38 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2022 | 2021 | Y/Y change % | |
|---|---|---|---|
| 0001742927 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 18947874 | 4851602 | 290.55 |
| operating expenses | 24306608 | 10104513 | 140.55 |
| interest income | 182802 | 0 | NaN |
| interest expense | 182802 | 2414 | 7472.58 |
| ebitda | -24111899 | -10104513 | -138.63 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -24306608 | -10104513 | -140.55 |
| operating income ratio | 0 | 0 | NaN |
| net income | -24339292 | -8521876 | -185.61 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.25 | -0.58 | -115.52 |
Research and Development (R&D) Expenses: R&D Expenses decreased to 19 million in 2022 from 5 million in 2021 representing a change of 290.55%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 24 million in 2022 from 10 million in 2021 representing a change of 140.55%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -24 million in 2022 from -9 million in 2021 representing a change of -185.61%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.25 in 2022 from -1.25 in 2021 representing a change of -115.52%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -24 million in 2022 from -10 million in 2021 representing a change of -138.63%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -24 million in 2022 from -10 million in 2021 representing a change of -140.55%. The increase in operating income indicates better operational performance and increased profitability.
| 2023Q3 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0001742927 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 8717273 | 8991250 | -3.05 |
| operating expenses | 10709047 | 12070551 | -11.28 |
| interest income | 91763 | 103080 | -10.98 |
| interest expense | 5901 | 12759 | -53.75 |
| ebitda | -10612090 | -11967490 | 11.33 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -10709047 | -12070551 | 11.28 |
| operating income ratio | 0 | 0 | NaN |
| net income | -10491029 | -12442862 | 15.69 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.44 | -0.55 | 20.00 |
Research and Development (R&D) Expenses: R&D Expenses decreased to 9 million in 2023Q3 from 9 million in 2023Q2 representing a change of -3.05%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -11 million in 2023Q3 from -12 million in 2023Q2 representing a change of 11.33%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -11 million in 2023Q3 from -12 million in 2023Q2 representing a change of 11.28%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -10 million in 2023Q3 from -12 million in 2023Q2 representing a change of 15.69%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Operating Expenses: Operating Expenses decreased to 11 million in 2023Q3 from 12 million in 2023Q2 representing a change of -11.28%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.44 in 2023Q3 from -0.44 in 2023Q2 representing a change of 20.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2022 | 2021 | Y/Y change % | |
|---|---|---|---|
| 0001742927 | |||
| total assets | 18923675 | 31404001 | -39.74 |
| total liabilities | 6607279 | 2717541 | 143.13 |
| total equity | 12316396 | 28686460 | -57.07 |
| cash and cash equivalents | 18519856 | 29687944 | -37.62 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 18923675 | 31404001 | -39.74 |
| total non current assets | 0 | 0 | NaN |
| total current liabilities | 6039840 | 2344811 | 157.58 |
| total non current liabilities | 567439 | 372730 | 52.24 |
| common stock | 2045 | 1443 | 41.72 |
| retained earnings | -91171261 | -66831969 | -36.42 |
| total debt | 0 | 0 | NaN |
Total Assets: Total Assets decreased to 19 million in 2022 from 31 million in 2021 representing a change of -39.74%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 7 million in 2022 from 3 million in 2021 representing a change of 143.13%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 12 million in 2022 from 29 million in 2021 representing a change of -57.07%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 19 million in 2022 from 30 million in 2021 representing a change of -37.62%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 19 million in 2022 from 31 million in 2021 representing a change of -39.74%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 6 million in 2022 from 2 million in 2021 representing a change of 157.58%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -91 million in 2022 from -67 million in 2021 representing a change of -36.42%. This indicates an accumulated losses.
Common Stock: Common Stock increased to 0 in 2022 from 0 in 2021 representing a change of 41.72%. This indicates an increase in ownership interest.
| 2023Q3 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0001742927 | |||
| total assets | 5387041 | 11842022 | -54.51 |
| total liabilities | 13906473 | 10220835 | 36.06 |
| total equity | -8519432 | 1621187 | -625.51 |
| cash and cash equivalents | 4972298 | 11151582 | -55.41 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 5387041 | 11842022 | -54.51 |
| total non current assets | 0 | 0 | NaN |
| total current liabilities | 13033062 | 9208345 | 41.54 |
| total non current liabilities | 873411 | 1012490 | -13.74 |
| common stock | 2265 | 2265 | 0.00 |
| retained earnings | -120707695 | -110216666 | -9.52 |
| total debt | 222500 | 222500 | 0.00 |
Total Assets: Total Assets decreased to 5 million in 2023Q3 from 12 million in 2023Q2 representing a change of -54.51%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 14 million in 2023Q3 from 10 million in 2023Q2 representing a change of 36.06%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -9 million in 2023Q3 from 2 million in 2023Q2 representing a change of -625.51%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 5 million in 2023Q3 from 11 million in 2023Q2 representing a change of -55.41%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 5 million in 2023Q3 from 12 million in 2023Q2 representing a change of -54.51%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 13 million in 2023Q3 from 9 million in 2023Q2 representing a change of 41.54%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -121 million in 2023Q3 from -110 million in 2023Q2 representing a change of -9.52%. This indicates an accumulated losses.
| 2022 | 2021 | Y/Y change % | |
|---|---|---|---|
| 0001742927 | |||
| net change in cash | -11168088 | 20927482 | -153.37 |
| operating cash flow | -18960581 | -10668462 | -77.73 |
| free cash flow | -18960581 | -10668462 | -77.73 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 0 | 0 | NaN |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 176735 | 106713 | 65.62 |
| accounts payables | 3010688 | -498463 | 703.99 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 7773527 | 31497463 | -75.32 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 7792493 | 31595944 | -75.34 |
| cash at end of period | 18519856 | 29687944 | -37.62 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 29687944 | 8760462 | 238.89 |
Net Change in Cash: Net Change in Cash decreased to -11 million in 2022 from 21 million in 2021 representing a change of -153.37%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -19 million in 2022 from -11 million in 2021 representing a change of -77.73%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -19 million in 2022 from -11 million in 2021 representing a change of -77.73%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2022 from 0 million in 2021 representing a change of 65.62%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2022 from 0 million in 2021 representing a change of 703.99%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2023Q2 | 2023Q1 | Q/Q change % | |
|---|---|---|---|
| 0001742927 | |||
| operating cash flow | -5317227 | -7951397 | 33.13 |
| free cash flow | -5317227 | -7951397 | 33.13 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 0 | 0 | NaN |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 2620819 | 51527 | 4986.30 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -212291 | -659693 | 67.82 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 5213257 | 687093 | 658.74 |
| net change in cash | -103970 | -7264304 | 98.57 |
| cash at end of period | 11151582 | 11255552 | -0.92 |
| cash at beginning of period | 11255552 | 18519856 | -39.22 |
Net Change in Cash: Net Change in Cash increased to 0 million in 2023Q2 from -7 million in 2023Q1 representing a change of 98.57%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -5 million in 2023Q2 from -8 million in 2023Q1 representing a change of 33.13%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -5 million in 2023Q2 from -8 million in 2023Q1 representing a change of 33.13%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023Q2 from 1 million in 2023Q1 representing a change of 67.82%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Stock-Based Compensation: Stock-Based Compensation increased to 3 million in 2023Q2 from 0 million in 2023Q1 representing a change of 4986.3%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2022-12-31 | 2021-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2022 | 2021 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.25 | -0.58 | -116.45 |
| operating cash flow per share | -0.97 | -0.72 | -34.69 |
| free cash flow per share | -0.97 | -0.72 | -34.69 |
| cash per share | 0.95 | 2.01 | -52.72 |
| book value per share | 0.63 | 1.94 | -67.46 |
| tangible book value per share | 0.63 | 1.94 | -67.46 |
| shareholders equity per share | 0.63 | 1.94 | -67.46 |
| interest debt per share | 0.01 | 0.0 | 5638.99 |
| market cap | 82945035.75 | 42745536.27 | 94.04 |
| enterprise value | 64425179.75 | 13057592.27 | 393.39 |
| pe ratio | -3.41 | -5.02 | 32.06 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -4.37 | -4.01 | -9.18 |
| pfcf ratio | -4.37 | -4.01 | -9.18 |
| pb ratio | 6.73 | 1.49 | 351.95 |
| ptb ratio | 6.73 | 1.49 | 351.95 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -2.67 | -1.29 | -106.76 |
| ev to operating cash flow | -3.4 | -1.22 | -177.61 |
| ev to free cash flow | -3.4 | -1.22 | -177.61 |
| earnings yield | -0.29 | -0.2 | -47.19 |
| free cash flow yield | -0.23 | -0.25 | 8.41 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0.77 | 2.94 | -73.86 |
| current ratio | 3.13 | 13.39 | -76.61 |
| interest coverage | -132.97 | -4185.8 | 96.82 |
| income quality | 0.78 | 1.25 | -37.77 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 4.21 | 5.01 | -16.08 |
| roic | -1.98 | -0.35 | -460.36 |
| return on tangible assets | -1.29 | -0.27 | -373.97 |
| graham net net | 0.61 | 1.82 | -66.53 |
| working capital | 12883835 | 29059190 | -55.66 |
| tangible asset value | 12316396 | 28686460 | -57.07 |
| net current asset value | 12316396 | 28686460 | -57.07 |
| invested capital | 12883835 | 29059190 | -55.66 |
| average receivables | 0 | 0 | NaN |
| average payables | 2014927 | 758814.5 | 165.54 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -1.98 | -0.3 | -565.22 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -1.98 on 2022-12-31 from -0.30 on 2021-12-31, representing a change of -565.22%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 3.13 on 2022-12-31 from 13.39 on 2021-12-31, representing a change of -76.61%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -3.41 on 2022-12-31 from -5.02 on 2021-12-31, representing a change of 32.06%. Indicating an increase in the relative valuation of the company's stock.
| 2023-09-30 Q3 | 2023-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RVPH | |||
| calendar year | 2023 | 2023 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.44 | -0.55 | 21.30 |
| operating cash flow per share | None | -0.24 | NaN |
| free cash flow per share | None | -0.24 | NaN |
| cash per share | 0.21 | 0.5 | -58.38 |
| book value per share | -0.35 | 0.07 | -590.55 |
| tangible book value per share | -0.35 | 0.07 | -590.55 |
| shareholders equity per share | -0.35 | 0.07 | -590.55 |
| interest debt per share | 0.01 | 0.01 | -9.37 |
| market cap | 117284285.2 | 131467816.66 | -10.79 |
| enterprise value | 112534487.2 | 120538734.66 | -6.64 |
| pe ratio | -2.79 | -2.64 | -5.81 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | 0 | -24.72 | 100.00 |
| pfcf ratio | 0 | -24.72 | 100.00 |
| pb ratio | -13.77 | 81.09 | -116.98 |
| ptb ratio | -13.77 | 81.09 | -116.98 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -10.6 | -10.07 | -5.28 |
| ev to operating cash flow | 0 | -22.67 | 100.00 |
| ev to free cash flow | 0 | -22.67 | 100.00 |
| earnings yield | -0.09 | -0.09 | 5.49 |
| free cash flow yield | None | -0.04 | NaN |
| debt to equity | -0.03 | 0.14 | -119.03 |
| debt to assets | 0.04 | 0.02 | 119.82 |
| net debt to ebitda | 0.45 | 0.91 | -50.99 |
| current ratio | 0.41 | 1.29 | -67.86 |
| interest coverage | -1814.79 | -946.04 | -91.83 |
| income quality | 0 | 0.43 | -100.00 |
| dividend yield | None | 0 | NaN |
| payout ratio | None | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 1.87 | 0.95 | 96.49 |
| roic | 1.29 | -6.55 | 119.73 |
| return on tangible assets | -1.95 | -1.05 | -85.34 |
| graham net net | -0.37 | 0.04 | -996.03 |
| working capital | -7646021 | 2633677 | -390.32 |
| tangible asset value | -8519432 | 1621187 | -625.51 |
| net current asset value | -8519432 | 1621187 | -625.51 |
| invested capital | -7646021 | 2633677 | -390.32 |
| average receivables | 0 | 0 | NaN |
| average payables | 3963331 | 2754432.5 | 43.89 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | 1.23 | -7.68 | 116.04 |
| capex per share | None | 0 | NaN |
ROE: Return on Equity (ROE) increased to 1.23 on 2023-09-30 Q3 from -7.68 on 2023-06-30 Q2, representing a change of 116.04%. Suggesting the company has been generating high returns for its shareholders.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.03 on 2023-09-30 Q3 from 0.14 on 2023-06-30 Q2, representing a change of -119.03%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.79 on 2023-09-30 Q3 from -2.64 on 2023-06-30 Q2, representing a change of -5.81%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.41 on 2023-09-30 Q3 from 1.29 on 2023-06-30 Q2, representing a change of -67.86%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Negative Sentiment: Discounted Cash Flow value is 0.95 which is lower than current price 1.14, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-11-14 17:25:00
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights.
Sentiment: Positive
Publish Date: 2024-11-06 08:00:00
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.
Sentiment: Negative
Publish Date: 2024-10-31 08:00:00
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.
Sentiment: Negative
Publish Date: 2024-10-08 08:00:00
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.
Sentiment: Positive
Publish Date: 2024-10-02 08:30:00
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.
Sentiment: Positive
Publish Date: 2024-08-21 06:00:00
CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of an underwritten offering of 4,761,905 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and investor warrants to purchase up to 4,761,905 shares of common stock. The combined offering price of each share of common stock and accompanying warrant sold in the offering (including the pricing for the warrant repricing described below) will be equal to $1.05, priced at-the-market under the Nasdaq rules. The combined offering price of each pre-funded warrant and accompanying warrant sold in the offering will be equal to $1.0499. The warrants have an exercise price of $0.7964 per share, will be immediately exercisable and will expire five years following the date of issuance. The pre-funded warrants have an exercise price of $0.0001 per share, will be immediately exercisable and may be exercised at any time after their original issuance. The offering is expected to close on or about August 22, 2024, subject to customary closing conditions.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
